Viz.ai and Cortechs.ai have partnered to integrate quantitative MRI analysis into Viz.ai’s AI-powered care coordination platform, beginning with multiple sclerosis (MS). The collaboration combines Cortechs.ai’s advanced neuroimaging software with Viz.ai’s clinical workflow and communication infrastructure, enabling clinicians to access detailed MRI-based insights within the same platform they use to coordinate patient care. The companies aim to improve the diagnosis, monitoring and management of MS while creating a more connected workflow across healthcare teams.
Multiple sclerosis is a complex neurological disease that often requires a combination of clinical evaluation and imaging to diagnose and monitor disease progression. Through the partnership, clinicians will be able to use Cortechs.ai’s NeuroQuant MS software directly within Viz.ai’s Neuro Suite to measure brain lesions, assess disease burden and track changes over time. By integrating these quantitative imaging tools into existing clinical workflows, the companies hope to reduce delays in diagnosis, improve treatment planning and provide more consistent longitudinal monitoring for patients with MS.
The collaboration also reflects Viz.ai’s continued expansion beyond stroke and neurovascular care into broader neurological and chronic disease management. With deployment potential across more than 2,000 hospitals and health systems, the integrated platform is intended to make advanced neuroimaging analysis more widely available while supporting coordinated care across providers. Both companies view the partnership as a foundation for expanding AI-powered imaging and workflow solutions to additional neurodegenerative diseases in the future.
Click here to read the original news story.
